On October 13, 2025, Soleno Therapeutics appointed Mark W. Hahn to its Board of Directors and Audit Committee, expanding the board size, with Hahn set to serve until 2028. He brings nearly 30 years of experience, including successful product launches and significant transactions in the life sciences sector.